JPMorgan Chase & Co. Has $861,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

JPMorgan Chase & Co. increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 172.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 562,764 shares of the biotechnology company's stock after acquiring an additional 356,053 shares during the period. JPMorgan Chase & Co. owned about 0.37% of Heron Therapeutics worth $861,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Anfield Capital Management LLC grew its holdings in shares of Heron Therapeutics by 5.6% during the fourth quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock worth $182,000 after purchasing an additional 6,264 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock valued at $1,692,000 after acquiring an additional 9,418 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Heron Therapeutics by 10.6% in the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 10,909 shares during the last quarter. Cutter & CO Brokerage Inc. lifted its position in shares of Heron Therapeutics by 69.6% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 13,600 shares in the last quarter. Finally, Apeiron RIA LLC grew its stake in shares of Heron Therapeutics by 7.8% during the fourth quarter. Apeiron RIA LLC now owns 262,542 shares of the biotechnology company's stock valued at $402,000 after purchasing an additional 19,000 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Trading Down 1.7 %

Shares of HRTX traded down $0.04 on Friday, reaching $2.31. 1,458,539 shares of the company's stock were exchanged, compared to its average volume of 2,306,930. The business has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $1.80. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The stock has a market capitalization of $351.88 million, a P/E ratio of -12.83 and a beta of 1.39.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. Equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HRTX. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th. StockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.